Else Marit Inderberg

Oslo University Hospital

Papers

1

Total Citations

30

H-Index

1

About

Else Marit Inderberg is a leading immunologist whose work bridges dendritic cell biology and cancer immunotherapy, with a particular focus on prostate cancer. Her key research areas include personalized cancer vaccines, T-cell responses, and adjuvant immunotherapy strategies. Inderberg’s major contribution is the pioneering long-term Phase I/II study of an adjuvant dendritic cell vaccine for high-risk prostate cancer patients after radical prostatectomy—a first-in-man trial that demonstrated the feasibility and safety of personalized DC vaccination in reducing biochemical relapse. This landmark work, published in 2021 and garnering over 30 citations, has opened new avenues for preventing disease recurrence in patients with aggressive prostate cancer. Her research is notable for its translational impact, combining cutting-edge cellular therapy with rigorous clinical evaluation. Inderberg’s achievements include advancing the understanding of how to harness the immune system to target residual tumor cells, offering hope for improved outcomes in high-risk cancer patients. Her work continues to inspire researchers exploring personalized immunotherapies.

Research Focus

Key Achievements

1
H-Index
1
Papers
30
Total Citations
30
Avg Citations/Paper
🏆 Most Cited Paper
Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomy
30 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 18
🏛 Institutions: Oslo University Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago